

## Medical Coverage Policy | Transcranial Magnetic Stimulation (TMS)



**EFFECTIVE DATE:** 09 | 01 | 2025

**POLICY LAST REVIEWED:** 05 | 07 | 2025

### OVERVIEW

Transcranial magnetic stimulation (TMS) is a noninvasive method of delivering electrical stimulation to the brain. The technique involves the placement of a small coil over the scalp and the passing of a rapidly alternating current through the coil wire. The electrical current produces a magnetic field that passes unimpeded through the scalp and bone and stimulates neuronal function. Repetitive TMS is being evaluated for the treatment of treatment-resistant depression (TRD) and other psychiatric and neurologic disorders. A variety of TMS modalities have been developed, which differ on parameters including stimulation intensity, frequency, pattern, and site of the brain stimulation. In conventional TMS, high frequency stimulation is delivered over the left dorsolateral prefrontal cortex (DLPFC) or low frequency stimulation over the right DLPFC. In bilateral TMS, both procedures are performed in the same session. Deep TMS employs an H-coil helmet designed to encompass a broader surface area and stimulate deeper brain structures than conventional TMS. Theta burst stimulation is administered at lower intensities and shorter intervals than conventional TMS.

### MEDICAL CRITERIA

Not applicable

### NOTIFICATION OF ADMISSION

Not applicable

### POLICY STATEMENT

#### Medicare Advantage Plans and Commercial Products

Transcranial magnetic stimulation (TMS) of the brain using an FDA-cleared device is considered medically necessary when filed with a covered ICD-10 code (refer to the Coding section for details) for individuals over age 18 years with major depressive disorder or obsessive-compulsive disorder who have had an inadequate response to pharmacological agents and psychotherapy services. Please refer to the policy, Behavioral Health Outpatient Professional Services for specialties that may provide TMS services.

Note: TMS practitioner certification is required and should be tailored for specialty providers who directly oversee and administer TMS. This certification requires a deeper understanding of the mechanisms behind TMS, along with the ability to diagnose conditions, tailor treatment plans, and evaluate outcomes. This comprehensive training allows providers to integrate TMS effectively within broader therapeutic strategies.

Indications for which TMS of the brain for the treatment of all other psychiatric and neurologic disorders is not covered for Medicare Advantage Plans and not medically necessary for Commercial Products includes but is not limited to bipolar disorder, generalized anxiety disorder, panic disorder, posttraumatic stress disorder, schizophrenia, substance use disorder and craving, amyotrophic lateral sclerosis, chronic pain, epilepsy, fibromyalgia, Alzheimer's disease, Parkinson disease, stroke recovery, or migraine headaches as the evidence is insufficient to determine the effects of the technology on health outcomes.

For more information, please contact BCBSRI Behavioral Health Utilization Management at 1-800-274-2958.

### COVERAGE

Benefits may vary by groups and contract. Please refer to the appropriate Evidence of Coverage and Subscriber Agreement for applicable behavioral health benefits/coverage.

## BACKGROUND

Transcranial magnetic stimulation was first introduced in 1985 as a new method of non-invasive stimulation of the brain. The technique involves placement of a small coil over the scalp and passing a rapidly alternating current through the coil wire, which produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex. TMS was initially used to investigate nerve conduction; for example, TMS over the motor cortex will produce a contralateral muscular-evoked potential. The motor threshold, which is the minimum intensity of stimulation required to induce a motor response, is empirically determined for each individual by localizing the site on the scalp for optimal stimulation of a hand muscle, then gradually increasing the intensity of stimulation. The stimulation site for treatment is usually 5 cm anterior to the motor stimulation site. Interest in the use of TMS as a treatment for depression was augmented by the development of a device that could deliver rapid, repetitive stimulation. Imaging studies had shown a decrease in the activity of the left dorsolateral prefrontal cortex in depressed patients, and early studies suggested that high-frequency (eg, 5 to 10 Hz) TMS of the left dorsolateral prefrontal cortex had antidepressant effects. In contrast to electroconvulsive therapy (ECT), TMS does not require general anesthesia and does not generally induce a convulsion. Repetitive TMS (rTMS) is also being tested as a treatment for a variety of other psychiatric and neurologic disorders.

Unlike major depressive disorder (MDD), which tends to be an episodic illness, OCD is a chronic lifelong disorder that typically begins in adolescence. It is the fourth most common mental illness and can cause significant distress and disability. Patients exhibit obsessions, compulsions and avoidance symptoms, which are correlated to abnormal activity in the cortico-stria to-thalamic-cortical circuit. Severe refractory cases are referred for neurosurgery (lesional or with an implanted brain stimulator). There is now a non-invasive approach using TMS to target the abnormal circuitry of OCD. In this approach, a coil is placed over the anterior cingulate cortex, which is 4 cm anterior to the foot motor cortex and beneath the dorsomedial prefrontal cortex. TMS for OCD is performed 5 days per week for 6 weeks for a total of 29 sessions. Prior to each treatment, patients undergo individually tailored provocations to activate the abnormal OCD circuitry (for instance, asking a person with germ-related obsessions and compulsions to touch the floor and then not use hand sanitizer). There is no need for anesthesia or analgesia and there are no activity restrictions before or after treatment (e.g., driving, working, operating heavy machinery). Other non-invasive treatments for OCD include cognitive behavioral therapy (CBT) and pharmacotherapy. CBT specific to OCD is known as exposure and response prevention (ERP), utilizing a trained cognitive behavioral therapist to guide the treatment. Pharmacotherapy options include serotonin reuptake inhibitors (SRIs), such as fluoxetine, paroxetine, sertraline and fluvoxamine, and the predominantly serotonergic tricyclic antidepressant clomipramine.

Conventional TMS delivers repeated electromagnetic pulses to induce prolonged modulation of neural activity, typically applied over the dorsolateral prefrontal cortex. High-frequency rTMS (usually  $\geq 10$  Hz) induces an increase in neural activity whereas low-frequency TMS (usually  $\leq 1$  Hz) has the opposite effect. If both procedures are performed in the same session, the intervention is described as bilateral rTMS.

A variety of TMS modalities have been developed, which differ on parameters including stimulation intensity, frequency, pattern, and site of the brain stimulation. Deep TMS employs an H-coil helmet design to encompass a broader surface area and stimulate deeper brain structures than conventional TMS. Theta burst stimulation is administered at lower intensities and shorter intervals than conventional rTMS.

Devices for transcranial stimulation have been cleared for marketing by the U.S. Food and Drug Administration (FDA) for diagnostic uses (FDA Product Code: GWF). A number of devices subsequently received FDA clearance for the treatment of major depressive disorder in adults who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Some of these devices use deep TMS or theta burst protocols. For example, the Brainsway Deep TMS system was FDA cleared for treatment-resistant depression in 2013 based on substantial equivalence to the Neurostar TMS Therapy System, and the Horizon (Magstim) and MagVita (Tonica Elektronik) have FDA clearance for their theta burst protocols.

Indications were expanded to include treating pain associated with certain migraine headaches in 2013, and obsessive-compulsive disorder in 2018.

In 2014, eNeura Therapeutics received 510(k) marketing clearance for the SpringTMS® for the treatment of migraine headaches. The device differs from the predicate Cerena™ TMS device with the addition of an LCD screen, a use authorization feature, a lithium battery pack, and a smaller size. The stimulation parameters are unchanged. The sTMS Mini (eNeura Therapeutics) received marketing clearance by the FDA in 2016. FDA product code: OKP.

In August 2018, the Deep TMS System (Brainsway) was granted a de novo 510(k) classification by the FDA as an adjunct for the treatment of adult patients with obsessive-compulsive disorder. The new classification applies to this device and substantially equivalent devices of this generic type.

The NeoPulse, now known as NeuroStar® TMS, was granted a de novo 510(k) classification by the FDA in 2008. The de novo 510(k) review process allows novel products with moderate or low-risk profiles and without predicates, which would ordinarily require premarket approval as a class III device, to be down-classified in an expedited manner and brought to market with a special control as a class II device. In 2014, the Cerena™ TMS device (eNeura Therapeutics) was granted a de novo 510(k) classification by the FDA for the acute treatment of pain associated with migraine headache with aura.

For individuals who have treatment-resistant depression (TRD) who receive TMS, the evidence includes a large number of sham-controlled randomized controlled trials (RCTs) and meta-analyses of these trials. Relevant outcomes are symptoms, functional outcomes, and quality of life. Meta-analyses found improved response rates and rates of remission for conventional TMS and theta burst stimulation compared with sham TMS. Additionally, a head-to-head trial showed noninferiority of theta burst stimulation to conventional TMS, with no difference in the incidence of adverse events. Meta-analyses have concluded that the effect of TMS on average depression scores is smaller than the effect of electroconvulsive therapy (ECT) on TRD and that the mean improvement in depression scores with TMS did not reach the minimal clinically important difference; however, clinically meaningful improvements were noted in a subgroup of studies using higher frequency pulses. One potential area of benefit for TMS is in accelerating or enhancing the response to antidepressant medications, and there is some evidence that TMS, when given in conjunction with the initiation of pharmacologic therapy, improves the response rate compared with pharmacologic therapy alone. The effect of TMS appears to be less robust when it is given in combination with a stable dose of antidepressant medication. Meta-analyses have also found that the efficacy of TMS decreases with longer follow-up, though some studies have reported a persistent response up to 6 months in some patients. There is limited evidence to compare the effects of these treatments on cognition, although the adverse events of TMS appear to be minimal. While meta-analyses have reported that the effect of TMS is smaller than the effect of ECT on TRD, because TMS does not require general anesthesia or induce seizures, some individuals may decline ECT so the balance of incremental benefits and harms associated with TMS may be reasonable compared with ECT. Based on the short-term benefit observed in RCTs and the lack of alternative treatments aside from ECT in patients with TRD, TMS may be considered a treatment option in patients with TRD who meet specific criteria. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have obsessive-compulsive disorder (OCD) who receive TMS, the evidence includes a number of small-to-moderate sized sham-controlled double-blind RCTs and meta-analyses of these studies. Relevant outcomes are symptoms, functional outcomes, and quality of life. A meta-analysis of 15 RCTs (N=483, range 18-65) conducted in 2016, found a benefit of TMS on patient-reported OCD symptom severity at time points ranging from 2 to 6 weeks, but there was substantial variability in the stimulation parameters, including the cortical region that was stimulated and the frequency of stimulation. A meta-analysis conducted in 2021 included 26 RCTs. The primary analysis found a significant effect of rTMS compared to sham on OCD symptoms, but the effect seemed to last only until 4 weeks after the last treatment. The RCT that was the basis of FDA clearance of deep TMS for treatment of OCD compared deep TMS to sham in 99 patients for 6 weeks, with an additional 4 weeks of follow-up as a secondary outcome.

Using a modified intention-to-treat (ITT) analysis (n=94), there was a larger mean decrease from baseline (improvement) on the Yale-Brown Obsessive-Compulsive Scale (YBOCS) score (the primary efficacy outcome) in the active treatment group (-6.0 points) than the sham group (-2.8 points), translating to a moderate effect size of 0.69. At 6 weeks, the response rate was 38.1% in the active treatment group compared to 11.1% in the sham group (p=.003), as measured by a 30% or greater increase in the YBOCS. The difference in the primary outcome measure between active and sham groups was not statistically significant in the ITT analysis. There was a benefit for TMS on clinician-reported measures of improvement. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have migraine headaches who receive TMS, the evidence includes a systematic review(n=8 trials) and a sham-controlled RCT of 201 patients conducted for submission to the Food and Drug Administration (FDA) for clearance in 2013. Relevant outcomes are symptoms, functional outcomes, and quality of life. The systematic review found that repetitive TMS (rTMS) reduced migraine pain intensity and frequency compared to sham; it was unclear whether patients were receiving background pharmacotherapy. The trial results were limited by the 46% dropout rate and the use of a post hoc analysis. No recent studies have been identified with these devices. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have psychiatric or neurological disorders other than depression, migraine, or OCD (eg, bipolar disorder, generalized anxiety disorder, panic disorder, posttraumatic stress disorder, schizophrenia, substance use disorder and craving, amyotrophic lateral sclerosis, chronic pain, epilepsy, fibromyalgia, Parkinson disease, stroke recovery) who receive TMS, the evidence includes numerous small RCTs and meta-analyses of these randomized trials. Relevant outcomes are symptoms, functional outcomes, and quality of life. The trials included in the meta-analyses are typically small and of low methodologic quality. In addition, stimulation parameters have not been established, and trial results are heterogeneous. There are no large, high-quality trials for any of these conditions demonstrating efficacy or the durability of any treatment effects. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## **CODING**

### **Medicare Advantage Plans and Commercial Products**

The following CPT code(s) are covered when filed with a covered ICD-10 code below, and are otherwise not covered for Medicare Advantage Plans and not medically necessary Commercial Products:

- 0889T** Personalized target development for accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation derived from a structural and resting-state functional MRI, including data preparation and transmission, generation of the target, motor threshold—starting location, neuronavigation files and target report, review and interpretation (Report 0889T once per personalized target development) (Do not report 0889T in conjunction with 70551, 70552, 70553, 70554, 70555 for the same session) (Do not report 0889T in conjunction with 77022) (New Code Effective 7/1/2024)
- 0890T** Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including target assessment, initial motor threshold determination, neuronavigation, delivery and management, initial treatment day (Report 0890T once on the first day of the course of treatment) (Do not report 0890T in conjunction with 77022) (New Code Effective 7/1/2024)
- 0891T** Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent treatment day (Do not report 0891T in conjunction with 77022) (New Code Effective 7/1/2024)
- 0892T** Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent motor threshold redetermination with delivery and management, per treatment day (Do not report 0892T in conjunction with 77022) (Do not report 0892T in conjunction with 0890T, 0891T on the same day) (New Code Effective 7/1/2024)
- 90867** Therapeutic repetitive transcranial magnetic stimulation treatment planning
- 90868** Therapeutic repetitive transcranial magnetic stimulation treatment delivery and management, per

session  
**90869** Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management

#### **Covered ICD-10 Code List**

F32.0  
F32.1  
F32.2  
F32.3  
F32.4  
F32.5  
F32.81  
F32.89  
F32.9  
F32.A  
F33.0  
F33.1  
F33.2  
F33.3  
F33.40  
F33.41  
F33.42  
F33.8  
F33.9  
F42.2  
F42.8  
F42.9

#### **RELATED POLICIES**

Behavioral Health Services Inpatient and Intermediate Levels of Care  
Behavioral Health Outpatient Professional Services

#### **PUBLISHED**

Provider Update, July 2025  
Provider Update, February 2024  
Provider Update, March 2023  
Provider Update, September 2021  
Provider Update, September 2020

#### **REFERENCES**

1. Centers for Medicare and Medicaid Services (CMS) Local Coverage Determination (LCD), Transcranial Magnetic Stimulation (L33398)
2. Centers for Medicare and Medicaid Services (CMS) Local Coverage Determination (LCD) Article, Billing and Coding: Transcranial Magnetic Stimulation (A57528))
3. FDA Briefing Document Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management (DSaRM) Advisory Committee Meeting February 12, 2019.  
<https://www.fda.gov/media/121376/download>. Accessed September 26, 2022.
4. Zimmerman M, Chelminski I, Posternak M. A review of studies of the Montgomery-Asberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression. *Int Clin Psychopharmacol*. Jan 2004; 19(1): 1-7. PMID 15101563
5. Center for Drug Evaluation and Research Application Number: 211243Orig1s000 Summary Review [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2019/211243Orig1s000SumR.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211243Orig1s000SumR.pdf). Accessed August 18, 2024.

6. Alphs L, Fu D-J, Williamson D, et al. Validation and mapping of the Suicidal Ideation and Behavior Assessment Tool (SIBAT). (abstract W88) *Neuropsychopharmacology*. 2018;43:S427S428.
7. Gross M, Nakamura L, Pascual-Leone A, et al. Has repetitive transcranial magnetic stimulation (rTMS) treatment for depression improved? A systematic review and meta-analysis comparing the recent vs. the earlier rTMS studies. *Acta Psychiatr Scand*. Sep 2007; 116(3): 165-73. PMID 17655557
8. Schutter DJ. Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis. *Psychol Med*. Jan 2009; 39(1): 65-75. PMID 18447962
9. Sehatzadeh Sh, Tu HA, Palimaka S, et al. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Ont Health Technol Assess Ser*. 2016; 16(5): 1-66. PMID 27099642
10. Brunoni AR, Chaimani A, Moffa AH, et al. Repetitive Transcranial Magnetic Stimulation for the Acute Treatment of Major Depressive Episodes: A Systematic Review With Network Meta-analysis. *JAMA Psychiatry*. Feb 01 2017; 74(2): 143-152. PMID 28030740
11. Voigt JD, Leuchter AF, Carpenter LL. Theta burst stimulation for the acute treatment of major depressive disorder: A systematic review and meta-analysis. *Transl Psychiatry*. May 28 2021; 11(1): 330. PMID34050123
12. Papakostas GI, Trivedi MH, Shelton RC, et al. Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD)a randomized clinical trial. *Mol Psychiatry*. Aug 2024; 29(8): 2287-2295. PMID 38454079
13. Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. *Lancet*. Apr 28 2018; 391(10131): 1683-1692. PMID 29726344
14. Food and Drug Administration. 510(k) Summary: Brainsway deep TMS System (K122288). 2013; [https://www.accessdata.fda.gov/cdrh\\_docs/pdf12/k122288.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf12/k122288.pdf). Accessed August 20, 2024.
15. Kedzior KK, Reitz SK, Azorina V, et al. Durability of the antidepressant effect of the high-frequency repetitive transcranial magnetic stimulation (rTMS) In the absence of maintenance treatment in major depression: a systematic review and meta-analysis of 16 double-blind, randomized, sham-controlled trials. *Depress Anxiety*. Mar 2015; 32(3): 193-203. PMID 25683231
16. Dunner DL, Aaronson ST, Sackeim HA, et al. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. *J Clin Psychiatry*. Dec 2014; 75(12): 1394-401. PMID 25271871
17. Richieri R, Guedj E, Michel P, et al. Maintenance transcranial magnetic stimulation reduces depression relapse: a propensity-adjusted analysis. *J Affect Disord*. Oct 2013; 151(1): 129-35. PMID 23790811
18. Connolly KR, Helmer A, Cristancho MA, et al. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. *J Clin Psychiatry*. Apr 2012; 73(4): e567-73. PMID22579164
19. Janicak PG, Nahas Z, Lisanby SH, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. *Brain Stimul*. Oct 2010; 3(4): 187-99. PMID 20965447
20. Saltychev M, Juhola J. Effectiveness of High-Frequency Repetitive Transcranial Magnetic Stimulation in Migraine: A Systematic Review and Meta-analysis. *Am J Phys Med Rehabil*. Nov 01 2022; 101(11):1001-1006. PMID 35034064
21. Food and Drug Administration. De Novo classification request for cerena transcranial magnetic stimulator (TMS) device. 2013; [https://www.accessdata.fda.gov/cdrh\\_docs/reviews/K130556.pdf](https://www.accessdata.fda.gov/cdrh_docs/reviews/K130556.pdf). Accessed August 20, 2024.
22. U.S. Food and Drug Administration. De novo classification request for Brainsway Deep Transcranial Magnetic Stimulation System. 2018; [https://www.accessdata.fda.gov/cdrh\\_docs/reviews/DEN170078.pdf](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170078.pdf). Accessed August 20, 2024.
23. Konstantinou G, Hui J, Ortiz A, et al. Repetitive transcranial magnetic stimulation (rTMS) in bipolar disorder: A systematic review. *Bipolar Disord*. Feb 2022; 24(1): 10-26. PMID 33949063

24. Tee MMK, Au CH. A Systematic Review and Meta-Analysis of Randomized Sham-Controlled Trials of Repetitive Transcranial Magnetic Stimulation for Bipolar Disorder. *Psychiatr Q*. Dec 2020; 91(4): 1225-1247. PMID 32860557
25. Cui H, Jiang L, Wei Y, et al. Efficacy and safety of repetitive transcranial magnetic stimulation for generalised anxiety disorder: A meta-analysis. *Gen Psychiatr*. 2019; 32(5): e100051. PMID 31673675
26. Li H, Wang J, Li C, et al. Repetitive transcranial magnetic stimulation (rTMS) for panic disorder in adults. *Cochrane Database Syst Rev*. Sep 17 2014; 2014(9): CD009083. PMID 25230088
27. Mantovani A, Aly M, Dagan Y, et al. Randomized sham controlled trial of repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex for the treatment of panic disorder with comorbid major depression. *J Affect Disord*. Jan 10 2013; 144(1-2): 153-9. PMID 22858212
28. Trevizol AP, Barros MD, Silva PO, et al. Transcranial magnetic stimulation for posttraumatic stress disorder: an updated systematic review and meta-analysis. *Trends Psychiatry Psychother*. 2016; 38(1):50-5. PMID 27074341
29. Brown R, Cherian K, Jones K, et al. Repetitive transcranial magnetic stimulation for post-traumatic stress disorder in adults. *Cochrane Database Syst Rev*. Aug 02 2024; 8(8): CD015040. PMID 39092744
30. He H, Lu J, Yang L, et al. Repetitive transcranial magnetic stimulation for treating the symptoms of schizophrenia: A PRISMA compliant meta-analysis. *Clin Neurophysiol*. May 2017; 128(5): 716-724. PMID 28315614
31. Dougall N, Maayan N, Soares-Weiser K, et al. Transcranial magnetic stimulation (TMS) for schizophrenia. *Cochrane Database Syst Rev*. Aug 20 2015; 2015(8): CD006081. PMID 26289586
32. Guan HY, Zhao JM, Wang KQ, et al. High-frequency neuronavigated rTMS effect on clinical symptoms and cognitive dysfunction: a pilot double-blind, randomized controlled study in Veterans with schizophrenia. *Transl Psychiatry*. Feb 25 2020; 10(1): 79. PMID 32098946
33. Kumar N, Vishnubhatla S, Wadhawan AN, et al. A randomized, double blind, sham-controlled trial of repetitive transcranial magnetic stimulation (rTMS) in the treatment of negative symptoms in schizophrenia. *Brain Stimul*. 2020; 13(3): 840-849. PMID 32289715
34. Zhuo K, Tang Y, Song Z, et al. Repetitive transcranial magnetic stimulation as an adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: a randomized, double-blind, sham-controlled trial. *Neuropsychiatr Dis Treat*. 2019; 15: 1141-1150. PMID 31190822
35. Zhu L, Zhang W, Zhu Y, et al. Cerebellar theta burst stimulation for the treatment of negative symptoms of schizophrenia: A multicenter, double-blind, randomized controlled trial. *Psychiatry Res*. Nov 2021;305: 114204. PMID 34587567
36. Jansen JM, Daams JG, Koeter MW, et al. Effects of non-invasive neurostimulation on craving: a meta-analysis. *Neurosci Biobehav Rev*. Dec 2013; 37(10 Pt 2): 2472-80. PMID 23916527
37. Chang CH, Liou MF, Liu CY, et al. Efficacy of Repetitive Transcranial Magnetic Stimulation in Patients With Methamphetamine Use Disorder: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. *Front Psychiatry*. 2022; 13: 904252. PMID 35711590
38. Fang J, Zhou M, Yang M, et al. Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease. *Cochrane Database Syst Rev*. May 31 2013;2013(5): CD008554. PMID 23728676
39. O'Connell NE, Wand BM, Marston L, et al. Non-invasive brain stimulation techniques for chronic pain. *Cochrane Database Syst Rev*. Apr 11 2014; (4): CD008208. PMID 24729198
40. O'Connell NE, Marston L, Spencer S, et al. Non-invasive brain stimulation techniques for chronic pain. *Cochrane Database Syst Rev*. Apr 13 2018; 4(4): CD008208. PMID 29652088
41. Jiang X, Yan W, Wan R, et al. Effects of repetitive transcranial magnetic stimulation on neuropathic pain: A systematic review and meta-analysis. *Neurosci Biobehav Rev*. Jan 2022; 132: 130-141. PMID34826512
42. Chen R, Spencer DC, Weston J, et al. Transcranial magnetic stimulation for the treatment of epilepsy. *Cochrane Database Syst Rev*. Aug 11 2016; (8): CD011025. PMID 27513825
43. Mishra A, Maiti R, Mishra BR, et al. Effect of Repetitive Transcranial Magnetic Stimulation on Seizure Frequency and Epileptiform Discharges in Drug-Resistant Epilepsy: A Meta-Analysis. *J Clin Neurol*. Jan 2020; 16(1): 9-18. PMID 31942753
44. Su YC, Guo YH, Hsieh PC, et al. Efficacy of Repetitive Transcranial Magnetic Stimulation in Fibromyalgia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Clin Med*. Oct12 2021; 10(20). PMID 34682790

45. Saltychev M, Laimi K. Effectiveness of repetitive transcranial magnetic stimulation in patients with fibromyalgia: a meta-analysis. *Int J Rehabil Res.* Mar 2017; 40(1): 11-18. PMID 27977465
46. Chou YH, Hickey PT, Sundman M, et al. Effects of repetitive transcranial magnetic stimulation on motor symptoms in Parkinson disease: a systematic review and meta-analysis. *JAMA Neurol.* Apr 2015; 72(4):432-40. PMID 25686212
47. Shirota Y, Ohtsu H, Hamada M, et al. Supplementary motor area stimulation for Parkinson disease: a randomized controlled study. *Neurology.* Apr 09 2013; 80(15): 1400-5. PMID 23516319
48. Li R, He Y, Qin W, et al. Effects of Repetitive Transcranial Magnetic Stimulation on Motor Symptoms in Parkinson's Disease: A Meta-Analysis. *Neurorehabil Neural Repair.* Jul 2022; 36(7): 395-404. PMID35616427
49. Hao Z, Wang D, Zeng Y, et al. Repetitive transcranial magnetic stimulation for improving function after stroke. *Cochrane Database Syst Rev.* May 31 2013; 2013(5): CD008862. PMID 23728683
50. Le Q, Qu Y, Tao Y, et al. Effects of repetitive transcranial magnetic stimulation on hand function recovery and excitability of the motor cortex after stroke: a meta-analysis. *Am J Phys Med Rehabil.* May 2014;93(5): 422-30. PMID 24429509
51. Li Y, Qu Y, Yuan M, et al. Low-frequency repetitive transcranial magnetic stimulation for patients with aphasia after stroke: A meta-analysis. *J Rehabil Med.* Sep 2015; 47(8): 675-81. PMID 26181486
52. Qiao J, Ye QP, Wu ZM, et al. The Effect and Optimal Parameters of Repetitive Transcranial Magnetic Stimulation on Poststroke Dysphagia: A Meta-Analysis of Randomized Controlled Trials. *Front Neurosci.*2022; 16: 845737. PMID 35573312
53. Zhang L, Xing G, Fan Y, et al. Short- and Long-term Effects of Repetitive Transcranial Magnetic Stimulation on Upper Limb Motor Function after Stroke: a Systematic Review and Meta-Analysis. *Clin Rehabil.* Sep 2017; 31(9): 1137-1153. PMID 28786336
54. Graef P, Dadalt MLR, Rodríguez DAMDS, et al. Transcranial magnetic stimulation combined with upper-limb training for improving function after stroke: A systematic review and meta-analysis. *J Neurol Sci.*Oct 15 2016; 369: 149-158. PMID 27653882
55. Murphy TK, Lewin AB, Storch EA, et al. Practice parameter for the assessment and treatment of children and adolescents with tic disorders. *J Am Acad Child Adolesc Psychiatry.* Dec 2013; 52(12):1341-59. PMID 24290467
56. McClintock SM, Reti IM, Carpenter LL, et al. Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression. *J Clin Psychiatry.* 2018; 79(1). PMID 28541649
57. VA/DoD Clinical Practice Guideline. (2022). The Management of Major Depressive Disorder. Washington, DC: U.S. Government Printing Office.  
<https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf>. Accessed August19, 2024.
58. VA/DoD Clinical Practice Guideline. (2023). VA/DoD Clinical Practice Guideline for Management of Bipolar Disorder. Washington, DC: U.S. Government Printing Office.  
<https://www.healthquality.va.gov/guidelines/MH/bd/VA-DoD-CPG-BD-Full-CPGFinal508.pdf>. Accessed August 20, 2024.
59. VA/DoD Clinical Practice Guideline. (2023). VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder. Washington, DC: U.S. Government Printing Office. <https://www.healthquality.va.gov/guidelines/MH/ptsd/VA-DoD-CPG-PTSD-Full-CPGAug242023.pdf>. Accessed August 18, 2024.
60. National Institute for Health and Care Excellence (NICE). Repetitive transcranial magnetic stimulation for depression [IPG542]. 2015; <https://www.nice.org.uk/guidance/ipg542>. Accessed August 17, 2024.
61. National Institute for Health and Care Excellence (NICE). Transcranial magnetic stimulation for treating and preventing migraine [IPG477]. 2014; <https://www.nice.org.uk/guidance/ipg477>. Accessed August20, 2024.
62. National Institute for Health and Care Excellence (NICE). Transcranial magnetic stimulation for auditory hallucinations [IPG680]. 2020; <https://www.nice.org.uk/guidance/ipg680/chapter/1-Recommendations>. Accessed August 18, 2024.

63. Leung A, Shirvalkar P, Chen R, et al. Transcranial Magnetic Stimulation for Pain, Headache, and Comorbid Depression: INS-NANS Expert Consensus Panel Review and Recommendation. *Neuromodulation*. Apr 2020; 23(3): 267-290. PMID 32212288
64. National Guideline Clearinghouse. Depression. The treatment and management of depression in adults.
65. Hayes, Inc., Hayes Emerging Technology Report. Neuro AD Therapy System for Alzheimer Disease. Lansdale, PA: Hayes, Inc.; 4/11/2019.
66. Hayes, Inc. Hayes Technology Assessment. High-Frequency Left Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Major Depressive Disorder. Lansdale, PA: Hayes, Inc. 11/3/2019.
67. Pridmore S, Erger S, May T. Second courses of transcranial magnetic stimulation (TMS) in major depression episodes for initial responders and non responders. *Malays J Med Sci*. 2019;26(3): 102–109.
68. Hayes, Inc. Hayes Technology Assessment. Transcranial Magnetic Stimulation for the Treatment of Obsessive-Compulsive Disorder. Lansdale, PA: Hayes, Inc. 04/21/2021.
69. Carmi L, Tendler A, Bystritsky A. et. al. Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder: A prospective multicenter randomized double-blind placebo controlled trial. *Am J Psychiatry*. 2019;176(11):931-938.
70. Roth Y, Tendler A, Arikan MK, et. al. Real world efficacy of deep TMS for obsessive compulsive disorder: Post marketing data collected from twenty-two clinical sites. *J of Psychiatric Res*. 2021;137:667-672.
71. TMS Society Inc. Coverage Guidelines for TMS for OCD. Fresno: Clinical TMS Society, Inc. 2021. Chen L, Hudaib AR, Hoy KE, Fitzgerald PB. Efficacy, efficiency and safety of high-frequency repetitive transcranial magnetic stimulation applied more than once a day in depression: A systematic review. *J Affect Disord*. 2020; 277:986-996. doi: 10.1016/j.jad.2020.09.035
72. Qiu H, Liang K, Lu L, et al. Efficacy and safety of repetitive transcranial magnetic stimulation in children and adolescents with depression: A systematic review and preliminary meta-analysis. *J Affect Disord*. 2023; 320:305-312. doi: 10.1016/j.jad.2022.09.060
73. Fitzsimmons SMDD, van der Werf YD, van Campen AD, et al. Repetitive transcranial magnetic stimulation for obsessive-compulsive disorder: A systematic review and pairwise/network meta-analysis. *J Affect Disord*. 2022;302:302-312. doi:10.1016/j.jad.2022.01.048
74. Liang K, Li H, Bu X, et al. Efficacy and tolerability of repetitive transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder in adults: A systematic review and network meta-analysis. *Transl Psychiatry*. 2021;11(1):332.. doi:10.1038/s41398-021-01453-0
75. Roth Y, Barnea-Ygael N, Carmi L, Storch EA, Tendler A, Zangen A. Deep transcranial magnetic stimulation for obsessive-compulsive disorder is efficacious even in patients who failed multiple medications and CBT. *Psychiatry Res*. 2020; 290:113179. doi:10.1016/j.psychres.2020.113179

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

